Welcome to our dedicated page for Adia Med news (Ticker: ADIA), a resource for investors and traders seeking the latest updates and insights on Adia Med stock.
ADIA Nutrition Inc. (ADIA) reports developments tied to its regenerative medicine, stem cell therapy, and biologic products business. The company operates through Adia Med clinics, which offer treatments such as PRP, AHSCT, orthopedic care, pain management, and wound repair, and through Adia Labs, which develops and sells biologic products including AdiaVita and AdiaLink.
Company news commonly covers clinical and regulatory activity involving AdiaVita, including study programs in chronic kidney disease, autism spectrum disorder, and chronic lower back pain. Updates also address operating results, product sales and medical-service revenue, capital-structure disclosures, governance matters, and the company's transition from a supplement-oriented business toward regenerative healthcare.
Adia Nutrition (OTCQB: ADIA) is rebranding to Adia Med, Inc. to reflect a shift to regenerative medicine, stem cell therapies, and biologic products. The company operates Adia Med clinics and Adia Labs, has an effective Form 10, and requested SIC code 2836 to align revenue classification with biologic products.
The name change is expected to complete in the coming months, subject to customary regulatory approvals; the ticker ADIA is expected to remain unchanged.
Adia Nutrition (OTCQB: ADIA) announced a strategic partnership with a leading Atlanta clinic to supply regenerative products for a new Autism Spectrum Disorder clinical study. The trial will enroll 100 participants, each receiving 3 infusions of AdiaVita (total 300 infusions); a single infusion is noted at about $8,000 as a price benchmark. Adia Med of Winter Park is separately recruiting for its own autism study starting May 2026. Adia Labs products are limited to research or IRB-approved studies and meet stated FDA quality and donor standards.
Adia Nutrition (OTCQB: ADIA) reported fiscal 2025 results and a strategic shift into regenerative medicine. Revenue rose to $700,508 from $6,380 in 2024, with gross profit of $191,670. The company recorded an operating loss of $366,492 and net loss of $395,464 and disclosed going-concern doubt.
Adia achieved full SEC reporting status in February 2026 and operates divisions Adia Med, Adia Labs, and Biolete while investing in R&D, clinical services, and infrastructure.
Adia Nutrition (OTCQB: ADIA) will host a live Zoom presentation tonight, March 24, 2026 at 6:00 PM EDT, with UCF CARD to explain an ongoing 24-month, IRB-approved clinical study (ClinicalTrials.gov ID: NCT07304440).
The trial is recruiting children ages 3–12 with autism and evaluates AdiaVita umbilical cord blood-derived stem cells and exosomes plus glutathione. Registration is free via Eventbrite and contact details are provided for enrollment and partnership inquiries.
Adia Nutrition (OTCQB: ADIA) appointed Amy Dalrymple, MSN, APRN, FNP-C, to lead its new Regenerative Aesthetics Division at Adia Med of Winter Park.
Dalrymple brings 11 years in aesthetic medicine; services launch with an open house on March 30, 2026 and patient treatments begin April 6, 2026.
Appointments, consultations, and licensing inquiries are available via adianutrition.com and adiamed.com or by phone at 321-788-0850.
Adia Med (OTCQB: ADIA) relaunched its website with ZenChange Marketing to centralize clinical research information, study summaries, enrollment details, and social media management. A highlighted initiative is the Autism Stem Cell Clinical Study (NCT07304440), a 24-month investigational trial with active recruitment and a one-time participation cost of $12,000.
The interventional phase is anticipated to begin in May 2026. The organization emphasizes investigational status, informed consent, medical oversight, and participant safety while using a patient-pay model without grants or government funding.
Adia Nutrition (OTCQB: ADIA) announced that subsidiary Adia Med submitted a final revised protocol to the Institutional Review Board on March 3, 2026, for a lower back pain study of AdiaVita.
The trial is a single-blind, placebo-controlled IV study randomizing ~100 participants with a three-month initial treatment and a crossover phase; patient-pay remains $5,000 per participant.
Adia Nutrition (OTCQB: ADIA) said its Adia Med Winter Park clinic is expanding into cosmetic services and is interviewing a Nurse Practitioner for hair growth and aesthetic procedures as of February 24, 2026. New offerings include microneedling and targeted hair-restoration treatments using Adia's high-concentration stem cell products such as AdiaVita (advertised as 100 million stem cells and 3.5 trillion exosomes per unit).
The clinic invites qualified candidates and potential licensing partners to contact Adia Med for roles, services, and strategic collaborations at the Winter Park location.
Adia Nutrition (OTCQB: ADIA) said subsidiary Adia Med submitted a second clinical study for IRB review on February 16, 2026, testing AdiaVita delivered intravenously for lower back pain. The single-blind, placebo-controlled trial will randomize about 100 participants and uses a three-month treatment then crossover design.
Participation is patient-pay at $5,000 per patient, with no extra cost for the crossover phase. Enrollment begins after IRB approval and ClinicalTrials.gov acceptance.
Adia Nutrition (OTCQB: ADIA) plans to launch four to five new clinical studies in 2026, expanding work with Adia Vita (umbilical cord blood-derived stem cells and exosomes).
Key initiatives include an IRB-approved Autism Spectrum Disorder (NCT07304440) expansion to include 13-year-olds and a new study evaluating Adia Vita in rheumatoid arthritis. The company is pursuing multi-site IRB approvals and partnerships to support nationwide research and continues recruiting for its 24-month ASD trial following BeyondBound IRB approval in late 2025.